Related Experiment Video

Updated: Aug 1, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

MNK Proteins as Therapeutic Targets in Leukemia

Candice Mazewski1,2, Leonidas C Platanias1,2,3

  • 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.

Oncotargets and Therapy
|April 28, 2023
PubMed

Insights

MAPK-interacting kinases (MNKs) are key in leukemia therapy resistance. Targeting MNKs shows promise for overcoming treatment challenges and improving patient survival in leukemia, particularly acute myeloid leukemia (AML).

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Therapy resistance significantly impacts leukemia patient survival.
  • MAPK-interacting kinases (MNKs) are implicated in oncogenic signaling and resistance mechanisms.
  • Acute myeloid leukemia (AML) models are central to investigating MNK roles.

Purpose of the Study:

  • To explore the potential of targeting MAPK-interacting kinases (MNKs) in leukemia treatment.
  • To evaluate MNK inhibitors as a strategy to overcome chemotherapy resistance in leukemia.
  • To advance the understanding of MNK-mediated mechanisms in cancer.

Main Methods:

  • Preclinical studies utilizing leukemia models.
  • Investigating combination therapies involving MNK inhibitors.
  • Assessing the efficacy of MNK inhibitors in chemotherapy-resistant leukemia cells.

Main Results:

  • Preclinical data demonstrate the efficacy of MNK inhibitors in combination formats.
  • MNK inhibition shows potential in treating chemotherapy-resistant leukemia cells.
  • Studies are actively optimizing MNK inhibitors for leukemia models.

Conclusions:

  • Targeting MNKs presents a promising therapeutic strategy for leukemia.
  • Further research and clinical trials are warranted to explore MNK inhibitors' potential.
  • Understanding MNK mechanisms in cancer could lead to improved clinical treatments.
Keywords:
AMLMAPKMNKeIF4Eresistance

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
215
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
79.0K